Mevalonate metabolism in cancer.
Cancer cells are characterized by sustained proliferative signaling, insensitivity to growth suppressors and resistance to apoptosis as well as by replicative immortality, the capacity to induce angiogenesis and to perform invasive growth. Additional hallmarks of cancer cells include the reprogramming of energy metabolism as well as the ability to evade immune surveillance. The current review focuses on the metabolic reprogramming of cancer cells and on the immune system's capacity to detect such changes in cancer cell metabolism. Specifically, we focus on mevalonate metabolism, which is a target for drug and immune based cancer treatment.
Cell Therapy Unit, Department of Urology, Innsbruck Medical University and Oncotyrol, K1 Center for Personalized Cancer Medicine, Austria.
Georg
G
Gruenbacher
Cell Therapy Unit, Department of Urology, Innsbruck Medical University and Oncotyrol, K1 Center for Personalized Cancer Medicine, Austria. Electronic address: martin.thurnher@i-med.ac.at.
Martin
M
Thurnher
D017209:Apoptosis; D049109:Cell Proliferation; D004734:Energy Metabolism; D005947:Glucose / Q000378:metabolism; D006019:Glycolysis / Q000502:physiology; D006801:Humans; D008798:Mevalonic Acid / Q000378:metabolism*; D009369:Neoplasms / Q000276:immunology / Q000378:metabolism* / Q000473:pathology*; D015398:Signal Transduction; D013601:T-Lymphocytes / Q000276:immunology; D019139:Tumor Escape / Q000276:immunology*; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism
D016159:Tumor Suppressor Protein p53; D005947:Glucose; D008798:Mevalonic Acid
Immune surveillance; Malignancy; Mevalonate; p53